143 related articles for article (PubMed ID: 386792)
1. Experience with 1,25-dihydroxycholecalciferol therapy in undergoing hemodialysis patients with progressive vitamin D2-treated osteodystrophy.
Prior JC; Cameron EC; Ballon HS; Lirenman DS; Moriarty MV; Price JD
Am J Med; 1979 Oct; 67(4):583-9. PubMed ID: 386792
[TBL] [Abstract][Full Text] [Related]
2. Long-term effects of small doses of 1,25-dihydroxycholecalciferol in renal osteodystrophy.
Ahmed KY; Varghese Z; Wills MR; Meinhard EA; Moorhead JF
Lancet; 1978 Mar; 1(8065):629-32. PubMed ID: 76168
[TBL] [Abstract][Full Text] [Related]
3. Hemodialysis patients with a unique mineralizing defect unresponsive to 1,25-dihydroxycholecalciferol. Dialysis osteomalacic syndrome.
Cameron EC; Prior JC; Ballon HS
Contrib Nephrol; 1980; 18():162-71. PubMed ID: 6986229
[TBL] [Abstract][Full Text] [Related]
4. Histopathology of renal osteodystrophy with particular reference to the effects of 1alpha-hydroxyvitamin D3 in patients treated by long-term haemodialysis.
Ellis HA; Pierides AM; Feest TG; Ward MK; Kerr DN
Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():31s-38s. PubMed ID: 606422
[TBL] [Abstract][Full Text] [Related]
5. Serum alkaline phosphatase in azotemic and hemodialysis osteodystrophy: a study of isoenzyme patterns, their correlation with bone histology, and their changes in response to treatment with 1alphaOHD3 and 1,25(OH)2D3.
Pierides AM; Skillen AW; Ellis HA
J Lab Clin Med; 1979 Jun; 93(6):899-909. PubMed ID: 438610
[TBL] [Abstract][Full Text] [Related]
6. The effects of calciferol and its metabolites on patients with chronic renal failure. II. Calcitriol, 1 alpha-hydroxyvitamin D3, and 24,25-dihydroxyvitamin D3.
Voigts AL; Felsenfeld AJ; Llach F
Arch Intern Med; 1983 Jun; 143(6):1205-11. PubMed ID: 6344827
[TBL] [Abstract][Full Text] [Related]
7. Variable response to long-term 1alpha-hydroxycholecalciferol in haemodialysis osteodystrophy.
Pierides AM; Ellis HA; Simpson W; Dewar JH; Ward MK; Kerr DN
Lancet; 1976 May; 1(7969):1092-5. PubMed ID: 57505
[TBL] [Abstract][Full Text] [Related]
8. Skeletal response to treatment with 1,25-dihydroxyvitamin D in renal failure.
Sherrard DJ; Coburn JW; Brickman AS; Singer FR; Maloney N
Contrib Nephrol; 1980; 18():92-7. PubMed ID: 7353382
[No Abstract] [Full Text] [Related]
9. Clinical effects of 1,25-dihydroxyvitamin D3 in uremic patients with overt osteodystrophy.
Brickman AS; Coburn JW; Sherrard DJ; Wong EG; Norman AW; Singer FR
Contrib Nephrol; 1980; 18():29-41. PubMed ID: 7353378
[No Abstract] [Full Text] [Related]
10. 1,25 dihydroxycholecalciferol effects in chronic dialysis. A double-blind controlled study.
Berl T; Berns AS; Hufer WE; Hammill K; Alfrey AC; Arnaud CD; Schrier RW
Ann Intern Med; 1978 Jun; 88(6):774-80. PubMed ID: 208439
[TBL] [Abstract][Full Text] [Related]
11. The effect of 1alpha(OH)D3 and 1alpha,25(OH)2D3 on the bone in patients with renal osteodystrophy.
Bordier P; Zingraff J; Gueris J; Jungers P; Marie P; Pechet M; Rasmussen H
Am J Med; 1978 Jan; 64(1):101-7. PubMed ID: 623125
[TBL] [Abstract][Full Text] [Related]
12. Calcium metabolism in renal failure.
David DS
Am J Med; 1975 Jan; 58(1):48-56. PubMed ID: 1090150
[TBL] [Abstract][Full Text] [Related]
13. The use of metabolites and analogues of vitamin D in prospective renal transplant recipients.
Cundy T; Kanis JA; Fraher L; Clemens TL; O'Riordan JL
Clin Nephrol; 1981 May; 15(5):240-5. PubMed ID: 7018772
[No Abstract] [Full Text] [Related]
14. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
15. [Treatment of uremic osteopathy. Effects of vitamin D metabolites and vitamin D analogs in chronic uremia and experimental renal insufficiency].
von Herrath D; Kraft D; Schaefer K; Krempien B
MMW Munch Med Wochenschr; 1974 Sep; 116(37):1573-8. PubMed ID: 4374654
[No Abstract] [Full Text] [Related]
16. Treatment of renal osteodystrophy with calciferol (vitamin D) and related steroids.
Brickman AS; Norman AW
Kidney Int; 1973 Aug; 4(2):161-7. PubMed ID: 4364427
[No Abstract] [Full Text] [Related]
17. Controlled trial of the effects of 1,25-dihydroxycholecalciferol in patients treated with regular dialysis.
Berl T; Berns AS; Huffer WE; Alfrey AC; Arnaud CD; Schrier RR
Contrib Nephrol; 1980; 18():72-81. PubMed ID: 6243528
[TBL] [Abstract][Full Text] [Related]
18. Effects of 6 months therapy with 1,25 (OH)2D3 on bone disease of dialysis patients.
Malluche HH; Goldstein DA; Massry SG
Contrib Nephrol; 1980; 18():98-104. PubMed ID: 7353383
[No Abstract] [Full Text] [Related]
19. Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure.
Andress DL; Norris KC; Coburn JW; Slatopolsky EA; Sherrard DJ
N Engl J Med; 1989 Aug; 321(5):274-9. PubMed ID: 2631697
[TBL] [Abstract][Full Text] [Related]
20. 1,25-dihydroxycholecalciferol. Effect on skeletal lesions and plasma parathyroid hormone levels in uremic osteodystrophy.
Brickman AS; Sherrard DJ; Jowsey J; Singer FR; Baylink DJ; Maloney N; Massry SG; Norman AW; Coburn JW
Arch Intern Med; 1974 Nov; 134(5):883-8. PubMed ID: 4613310
[No Abstract] [Full Text] [Related]
[Next] [New Search]
